PF-573228

PF-573228 is a potent and selective small molecule inhibitor of **focal adhesion kinase (FAK)**, a non-receptor protein tyrosine kinase involved in cell signaling pathways that regulate cell adhesion, migration, proliferation, survival, and angiogenesis. It displays ATP-competitive inhibition of FAK with an IC50 of 4 nM, offering 50–250-fold selectivity for FAK over other kinases. PF-573228 has been widely used in preclinical and laboratory research to study FAK-dependent cellular processes and is regarded as a tool compound for dissecting FAK’s function in cancer and inflammatory diseases. Preclinical evidence suggests inhibition of FAK by PF-573228 can reduce tumor cell survival, migration, and invasiveness and may have beneficial effects in models of acute lung injury, aortic aneurysm, and various cancers. Developed originally by Pfizer, PF-573228 is in a preclinical or “pending” R&D phase and is not used in humans as an approved therapeutic agent[1][4][5][6][7][10].

Other names

PF573228PF-573228PF 573228